Wongmekiat Orawan, Thamprasert Kamthorn
Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Fundam Clin Pharmacol. 2005 Oct;19(5):555-62. doi: 10.1111/j.1472-8206.2005.00361.x.
Cyclosporin A (CsA) nephrotoxicity has been described in solid organ recipients and in the patients who were treated for autoimmune diseases. Reactive oxygen species-induced oxidative stress and lipid peroxidations are implicated in the pathophysiology of CsA-induced renal injury. Aged garlic extract (AGE) has been reported to exhibit potent antioxidative and free radical scavenging abilities in various disease conditions. The present study was designed to investigate whether AGE could possibly have a protective effect against nephrotoxicity induced by CsA. Male Wistar rats were treated orally with CsA (50 mg/kg/day), CsA + AGE (0.25, 0.5, 1, and 2 g/kg/day started 3 days before the first dose of CsA), or the vehicle of CsA for a period of 10 days. Blood urea nitrogen, serum creatinine, creatinine clearance, and renal histopathological changes were evaluated after 24 h of the last treatment. CsA caused an increase in blood urea nitrogen and serum creatinine by 117 and 100%, respectively, whereas it decreased creatinine clearance by 78% compared with the vehicle-treated rats (all P < 0.001). AGE treatment (0.5, 1 and 2 g/kg) significantly protected animals against CsA-induced biochemical changes, albeit blood urea nitrogen and creatinine clearance in the 0.5 g/kg AGE treated-animals were only partially restored. Kidney sections taken from CsA-treated rats showed severe vacuolations and tubular necrosis. These histopathological changes were markedly improved by pretreatment of rats with AGE at the dose of 0.5--2 g/kg. The results indicate that AGE ameliorates renal dysfunction and morphological changes induced by CsA, and imply that it could be a beneficial remedy for attenuating the CsA nephrotoxicity.
环孢素A(CsA)肾毒性已在实体器官移植受者和接受自身免疫性疾病治疗的患者中有所描述。活性氧诱导的氧化应激和脂质过氧化与CsA诱导的肾损伤的病理生理学有关。据报道,陈年大蒜提取物(AGE)在各种疾病状态下具有强大的抗氧化和自由基清除能力。本研究旨在调查AGE是否可能对CsA诱导的肾毒性具有保护作用。雄性Wistar大鼠口服给予CsA(50mg/kg/天)、CsA + AGE(0.25、0.5、1和2g/kg/天,在首次给予CsA前3天开始)或CsA的赋形剂,持续10天。在最后一次治疗24小时后评估血尿素氮、血清肌酐、肌酐清除率和肾脏组织病理学变化。与赋形剂处理的大鼠相比,CsA使血尿素氮和血清肌酐分别增加了117%和100%,而肌酐清除率降低了78%(所有P < 0.001)。AGE处理(0.5、1和2g/kg)显著保护动物免受CsA诱导的生化变化影响,尽管0.5g/kg AGE处理的动物中的血尿素氮和肌酐清除率仅部分恢复。取自CsA处理大鼠的肾脏切片显示严重空泡化和肾小管坏死。用0.5 - 2g/kg剂量AGE预处理大鼠可明显改善这些组织病理学变化。结果表明,AGE可改善CsA诱导的肾功能障碍和形态学变化,这意味着它可能是减轻CsA肾毒性的有益疗法。